Signal2026-06-17
ClinicalTrials.gov

[PHASE3] Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Part of

Emerging Cancer Biomarker Techniques

Open primary sourceSee the whole picture